Fusidic Acid

Phase 3Small molecule

Roche

Fusidic Acid is one of 30 small molecule programs targeting Cutaneous Leishmaniasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cutaneous LeishmaniasisActive, not recruiting

Cutaneous LeishmaniasisPhase 3

Active, not recruiting

Competition

Competitive Landscape

56 competitors in Cutaneous Leishmaniasis

#DrugCompanyPhaseTrials

Levaquin

Garamycin

Abelcet

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—4

Impavido

KKnight Therapeutics (USA) Inc

Phase 3

12 5

Meglumine Antimoniate

UUniversity of Brasilia

Approved

14 6

Pentam

FFresenius Kabi Oncology Ltd.

Phase 3

2 7

Aldara

BBausch Health Americas, Inc.

Phase 3

1 8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 9

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 10

Cipro

Bayer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Not yet recruiting

Cutaneous Leishmaniasis

NCT06695143

Clinical

Trials by Indication[1]

Age1 trial

A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.

Completed· Roche logo

Roche·Phase 3·NCT00718315·201 enrolled

Colonization1 trial

S. Aureus Decolonization in HPN Patients.

Terminated·RRadboud University Medical Center·N/A·NCT03173053·63 enrolled

Cutaneous Leishmaniasis1 trial

Antimicrobial Adjuvants to Revert the Imbalance of Skin Microbiota for Improved Outcomes of Complicated Cutaneous Leishmaniasis Treatment in Ethiopia

Not yet recruiting·IInstitute of Tropical Medicine, Belgium·Phase 3·NCT06695143·180 enrolled

Catheter1 trial

Scars After Central Venous Catheters

Unknown status·MMette Møller Handrup·Phase 3·NCT01113125·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Fusidic Acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fusidic Acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fusidic Acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Fusidic Acid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Age1 trial

Colonization1 trial

Cutaneous Leishmaniasis1 trial

Catheter1 trial

References

Drug Info

Quick Facts

Related News